November-December 2003 - Volume 13 - Supplement 2
pp: 133-250

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

PICCART, M. J.; BERTELSEN, K.; STUART, G.; More

International Journal of Gynecological Cancer. 13:144-148, November-December 2003.

First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

KRISTENSEN, G. B.; VERGOTE, I.; STUART, G.; More

International Journal of Gynecological Cancer. 13:172-177, November-December 2003.

Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?

GONZÁLEZ-MARTÍN, A.; ON BEHALF OF GEICO GROUP (GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE OVARIO-SPANISH GROUP FOR INVESTIGATION ON OVARIAN CANCER), MADRID SPAIN

International Journal of Gynecological Cancer. 13:185-191, November-December 2003.

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

PICCART, M. J.; FLOQUET, A.; SCARFONE, G.; More

International Journal of Gynecological Cancer. 13:196-203, November-December 2003.